Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Dental Technology Can Help Reduce Patients In-Office Time
Technology is the way of the future, or at least the way of the American future, which is why dentists throughout the United States have increased their use of digital technology. And as making a better use of patients" two most useful res: time and money becomes increasingly important in the practice of dentistry, technology becomes the key to success. Dennis J. Fasbinder, DDS, MAGD, ABGD will help dentists decrease the amount of time that patients" spend in the office by leading a discussion and providing information about using computer-assisted design and computer-assisted machining (CAD/CAM) technology at the Academy of General Dentistry"s (AGD) 57th Annual Meeting, which is taking place in Baltimore, Md., July 8 - 12, 2009.
buy viagra
Senate HELP Panel Begins Mark Up Of Bill Placing Tobacco Under FDA Oversight
The Senate Health, Education, Labor and Pensions Committee on Tuesday began marking up a bill (S 982) that would allow FDA to regulate tobacco products, CongressDaily reports. The bill would allow FDA to place larger, color warning labels about the health risks of smoking on cigarette packs, as well as to regulate the marketing of tobacco products and advertising to children. The agency could not ban tobacco products or eliminate nicotine from cigarettes, but it could regulate their production and ban flavored cigarettes other than menthol. Sen. Chris Dodd (D-Conn.) said, "Over the years, this bill has been reviewed; it has been vetted; it has been debated, over and over and over again. The time has come to act." The House in April passed its version of the bill, 298-112 (Hunt, CongressDaily, 5/20). The committee by voice vote approved an amendment proposed by Sen. Jeff Merkley (D-Ore.) that would give FDA priority to review products that contain nicotine, such as candies. Committee ranking member Mike Enzi (R-Wyo.) proposed two amendments, one that would have given regulatory authority over tobacco to CDC and another that would have ordered FDA to study which flavors to ban, instead of a current provision that bans specific flavors. Both amendments were defeated. Enzi said, "I think the FDA is the wrong regulator. It approves cures, not poisons." The only Democrat who opposed the bill was Sen. Kay Hagan (N.C.), who said the measure would harm the tobacco industry in her home state (Armstrong, CQ HealthBeat, 5/19). The panel"s other member from North Carolina, Sen. Richard Burr (R), said he would filibuster the bill. He said, "I put my fellow senators on notice: This is something that will be a much longer time on the floor than it will be in this hearing" (CongressDaily, 5/20). The committee plans to continue marking up the bill Wednesday and possibly Thursday.The Obama administration has expressed its support for the bill (CQ HealthBeat, 5/19). FDA Commissioner Margaret Hamburg also has said her agency should regulate tobacco (Armstrong, CQ HealthBeat, 5/18).
plan for health
News of the day
Proteomics Technology To Focus On Neurological Complications Of HIV
The National Institute on Drug Abuse of the National Institutes of Health has awarded a three-year, $3-million grant to Albert Einstein College of Medicine of Yeshiva University to establish a research center to study the neurological complications that afflict people infected with HIV, the virus that causes AIDS.
Mental Health

Addex Partner Starts First-Ever Clinical Trial Of An MGluR Positive Allosteric Modulator

Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that its partner Ortho-McNeil- Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression and other CNS disorders, is the first PAM of any mGluR subtype to enter clinical trials. Targeting mGluR2 with a PAM is a novel approach that may offer advantages over classical drug approaches. In reaching this milestone, Addex received a EUR 1 million payment from OMP and remains eligible for additional development milestones and royalties. Allosteric modulators are a novel class drugs that exert their effects on a specific receptor by interacting with a different site than the traditional binding site used by traditional "orthosteric" drugs and the body"s natural activators (i.e. endogenous ligands), glutamate in this case. Allosteric molecules afford modulation of receptors that is different than orthosteric drugs. Furthermore, Addex believes it can find specific drug-like allosteric modulators with more success than others have had with orthosteric drug discovery. "We are proud to have been able, together with our partner, to discover and develop the first mGluR2 PAM to reach human beings," said Vincent Mutel, CEO of Addex. "Because activating mGluR2 has been recognized as one of the most promising strategies for treating anxiety and more recently, schizophrenia, developing an allosteric modulator, like ADX71149, specifically targeting this brain receptor has been an exciting scientific endeavor and we are looking forward to seeing how differentiated this modulatory approach will be in humans." Note for editors: An orthosteric agonist binds at the same site on a receptor as the endogenous ligand, in this case, glutamate. Much like flipping a light switch on, endogenous ligands or orthosteric agonists, effectively turn receptors on, sending a message to the cell to perform a specific function. By contrast, an allosteric modulator binds at a different site on the receptor than the endogenous ligand. As a result, an allosteric modulator does not turn on/off a receptor but rather exerts its influence only when the endogenous ligand also is binding (i.e. the switch is turned on). Thus, allosteric modulators act much more like a dimmer than an on/off switch. Positive allosteric modulators increase the signal sent into the cell by the receptor, while a negative allosteric modulators (NAM) reduce it. This approach may prove advantageous because it allows the body to maintain control over the physiological on/off rhythm - something that no orthosteric drug has been able to emulate - while affording a new kind of therapeutic influence at disease mediating receptors. Although no drug specifically targeting mGluR2 is marketed, a Phase II clinical study published in Nature Medicine in 2007 showed that an orthosteric mGluR2/3 agonist improved symptoms of schizophrenia with efficacy similar to a leading marketed drug for schizophrenia. Separately, a related orthosteric mGluR2/3 agonist has been shown to have efficacy in Phase II trials in patients with generalized anxiety disorder. Activation of mGluR2 also has been shown to be efficacious in multiple preclinical models of anxiety. Addex Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009